A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Completed

• Conditions: Myelofibrosis

• Registration Number: NCT05444972
• Lead Sponsor: AbbVie

Brief Summary

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.

Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.

Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.

There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-06-23
• Study First Submitted QC: 2022-06-30
• Study First Posted: 2022-07-06
• Study Start: 2022-08-23
• Primary Completion: 2023-11-14
• Study Completion: 2023-11-14
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-07
• Last Update Posted: 2023-12-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 998

Inclusion Criteria

• Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
• Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.

Exclusion Criteria

• Having received MF treatment in a clinical trial setting.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment	Up to Week 156	Time from diagnosis of MF to initial treatment.
Duration of Second Treatment	Up to Week 156	Duration of second treatment.
Duration of Initial Treatment	Up to Week 156	Duration of initial treatment.
Duration of Subsequent Treatments	Up to Week 156	Duration of subsequent treatments.

Trial Locations

Locations (66)

Hospital Italiano de Buenos Aires /ID# 244373; 🇦🇷 Ciudad Autonoma Buenos Aires, Ciuadad Autonoma De Buenos Aires, Argentina

Fundaleu /Id# 244371; 🇦🇷 Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina

Azienda Ospedaliera di Perugia /ID# 245415; 🇮🇹 Perugia, Umbria, Italy

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 247394; 🇧🇷 São Paulo, Sao Paulo, Brazil

Ospedale Belcolle /ID# 245726; 🇮🇹 Viterbo, Italy

Townsville University Hospital /ID# 246585; 🇦🇺 Douglas, Queensland, Australia

CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 250563; 🇨🇦 Montreal, Quebec, Canada

Centro Hospitalar e Universitario de Coimbra, EPE /ID# 244687; 🇵🇹 Coimbra, Portugal

Wellness Oncology & Hematology /ID# 255591; 🇺🇸 West Hills, California, United States

Centro Hospitalar Universitario de Sao Joao, EPE /ID# 244400; 🇵🇹 Porto, Portugal

Institutul Clinic Fundeni /ID# 245939; 🇷🇴 Bucharest, Romania

Gulhane Askeri Tip Academy /ID# 244134; 🇹🇷 Ankara, Turkey

Royal Perth Hospital /ID# 246586; 🇦🇺 Perth, Western Australia, Australia

St. Paul's Hospital /ID# 249719; 🇨🇦 Vancouver, British Columbia, Canada

Juravinski Cancer Centre /ID# 251334; 🇨🇦 Hamilton, Ontario, Canada

Nova Scotia Health /ID# 248393; 🇨🇦 Halifax, Nova Scotia, Canada

Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 245149; 🇮🇹 Cona, Ferrara, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 245335; 🇮🇹 Rome, Lazio, Italy

Azienda Ospedaliera Universitaria Paolo Giaccone /ID# 245075; 🇮🇹 Palermo, Italy

Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 244750; 🇲🇽 Monterrey, Nuevo Leon, Mexico

Hospital General de Mexico /ID# 244749; 🇲🇽 Ciudad de Mexico, Mexico

Specjalistyczna Praktyka Lekarska Witold Prejzner /ID# 250516; 🇵🇱 Gdańsk, Pomorskie, Poland

Joanna Góra-Tybor Specjalistyczna Praktyka Lekarska /ID# 250495; 🇵🇱 Łódź, Poland

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 250092; 🇨🇳 Kaohsiung, Taiwan

Dicle Universitesi Tip /ID# 244137; 🇹🇷 Diyarbakir, Turkey

Trakya University Medical Facu /ID# 244132; 🇹🇷 Edirne, Istanbul, Turkey

Bagcilar Medipol Mega Universite Hastanesi /ID# 244133; 🇹🇷 Istanbul, Turkey

Ege University Medical Faculty /ID# 244130; 🇹🇷 Izmir, Turkey

Inonu University Medical Faculty /ID# 244135; 🇹🇷 Malatya, Turkey

UAB Comprehensive Cancer Center /ID# 252767; 🇺🇸 Birmingham, Alabama, United States

Brigham & Women's Hospital /ID# 254312; 🇺🇸 Boston, Massachusetts, United States

Princess Margaret Cancer Centre /ID# 249748; 🇨🇦 Toronto, Ontario, Canada

Gabrail Cancer Center Research /ID# 252768; 🇺🇸 Canton, Ohio, United States

Royal Adelaide Hospital /ID# 246583; 🇦🇺 Adelaide, South Australia, Australia

Fiona Stanley Hospital /ID# 246584; 🇦🇺 Murdoch, Western Australia, Australia

Jewish General Hospital /ID# 250674; 🇨🇦 Montreal, Quebec, Canada

Organizacion Clinica Bonnadona -PREVENIR S.A.S. /ID# 244589; 🇨🇴 Baranquilla, Atlantico, Colombia

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 246165; 🇬🇷 Athens, Greece

METAXA Cancer Hospital of Piraeus /ID# 246164; 🇬🇷 Piraeus, Greece

IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 245716; 🇮🇹 Bologna, Italy

Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 245566; 🇮🇹 Novara, Italy

Hospital de Especialidades CMN SigloXXI /ID# 244748; 🇲🇽 Ciudad de México, Ciudad De Mexico, Mexico

Krzysztof Mądry Praktyka Lekarska /ID# 250485; 🇵🇱 Warsaw, Mazowieckie, Poland

Specjalistyczna Praktyka Lekarska Grzegorz Helbig /ID# 250515; 🇵🇱 Orzesze, Poland

General University Hospital of Alexandroupolis /ID# 246161; 🇬🇷 Alexandroupolis, Greece

Fundacion Santa Fe de Bogota /ID# 244588; 🇨🇴 Bogota, Cundinamarca, Colombia

Hospital Pablo Tobon Uribe /ID# 244525; 🇨🇴 Medellin, Colombia

University General Hospital of Patras /ID# 246162; 🇬🇷 RION Patras Achaia, Greece

Institutul Oncologic Prof Dr I Chiricuta /ID# 244393; 🇷🇴 Cluj Napoca, Romania

Instituto FIDES /ID# 245526; 🇦🇷 La Plata, Buenos Aires, Argentina

CSSS Alphonse-Desjardins, CHAU de Levis /ID# 250449; 🇨🇦 Levis, Quebec, Canada

Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 246108; 🇨🇴 Bogota DC, Cundinamarca, Colombia

University General Hospital of Ioannina /ID# 246160; 🇬🇷 Ioannina, Greece

ASST Spedali civili di Brescia /ID# 244910; 🇮🇹 Brescia, Italy

National Taiwan University Hospital /ID# 250093; 🇨🇳 Taipei City, Taiwan

Hacettepe University Medical Faculty /ID# 244131; 🇹🇷 Ankara, Turkey

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 247392; 🇧🇷 Sao Paulo, Brazil

University General Hospital of Heraklion PA.G.N.I /ID# 246163; 🇬🇷 Heraklion, Kriti, Greece

ASST Sette Laghi /ID# 245443; 🇮🇹 Varese, Italy

Clínica Imbanaco S.A.S /ID# 248465; 🇨🇴 Cali, Colombia

General Hospital of Athens Laiko /ID# 246159; 🇬🇷 Athens, Attiki, Greece

University General Hospital Attikon /ID# 246167; 🇬🇷 Athens, Attiki, Greece

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 244909; 🇮🇹 Milan, Italy

Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 248203; 🇵🇹 Lisboa, Portugal

MedLife - Policlinica de Diagnostic Rapid /ID# 244395; 🇷🇴 Brașov, Brasov, Romania

Spitalul Clinic Colentina /ID# 245620; 🇷🇴 Bucuresti, Romania